Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

Antibody based immune-checkpoint blockade therapy is a major breakthrough in oncology, leading to clinical benefit for cancer patients. Among the growing family of inhibitory receptors, the B and T lymphocyte attenuator (BTLA), which interacts with herpes virus entry mediator (HVEM), is a promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Spodzieja, Marta, Lach, Sławomir, Iwaszkiewicz, Justyna, Cesson, Valérie, Kalejta, Katarzyna, Olive, Daniel, Michielin, Olivier, Speiser, Daniel E., Zoete, Vincent, Derré, Laurent, Rodziewicz-Motowidło, Sylwia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464627/
https://www.ncbi.nlm.nih.gov/pubmed/28594868
http://dx.doi.org/10.1371/journal.pone.0179201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464627/
https://www.ncbi.nlm.nih.gov/pubmed/28594868
http://dx.doi.org/10.1371/journal.pone.0179201

Ejemplares similares